BeOne MedicinesONC

• Phase 1BGB-16673 재발·불응 B세포 혈액암 병용 임상모집 중A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
  76%
• Phase 3BGB-11417 만성 림프구성 백혈병 1차 치료 임상모집 중A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
  79%
• Phase 3손로토클락스 만성림프구성백혈병 병용요법 3상 임상모집 중A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
  79%
• Phase 1손로토클락스(BGB-11417) 다발골수종 병용/단독 1b/2상모집 중A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
  62%
• Phase 3만성 림프구성 백혈병 대상 BGB-11417 병용 비교 임상진행 중Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
  79%
• Phase 3Sonrotoclax·자누브루티닙 외투세포림프종 3상모집 중A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
  38%
• Phase 2손로토클락스+자누브루티닙 백혈병 1차 병용 임상진행 중A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
  72%
• Phase 1BGB-B2033 병용 및 단독 투여 진행성 고형암 1상 임상모집 중A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
  76%
• Phase 1BG-C137 고형암 타깃 ADC 항암제 첫 환자 투여 임상모집 중A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
  78%
• Phase 3기존 약물 불응 백혈병 대상 BGB-16673 비교 임상모집 중A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
  74%
• Phase 1진행성 말기 고형암 환자 대상 BG-C477 안전성 임상모집 중A Study of BG-C477 in Participants With Advanced Solid Tumors
  76%
• Phase 1BG-75098 진행성 고형암 단독·병용 임상모집 중A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
  48%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.